Special Issue

Drug Candidates for the Prevention and Treatment of Cardiovascular Diseases

Message from the Guest Editor

Cardiovascular diseases (CVDs) comprise the first leading cause of morbidity and mortality in the western world. Despite the great advances in pharmaceutical therapy, there is still an increasing need to develop and apply more effective medications for primary and secondary prevention of CVDs. The aim of the present Special Issue is to attract more than 10 high-quality papers that focus on drugs with potentiality to contribute to CVD prevention and treatment. Those drug candidates may be substances that target several aspects of pathophysiological mechanisms of CVDs or may comprise therapeutic regimes of other, noncardiovascular diseases, with potential expansion of their indications to CVDs. Among all, lipid lowering remains the cornerstone of prevention and treatment of CVDs. Novel, especially gene-oriented, lipid-lowering agents seem guite promising. Medicinal chemistry has introduced technological and conceptual innovations with wide potential application in CVDs.

Guest Editor

Dr. Nikolaos Kadoglou Medical School, University of Cyprus, 2029 Nicosia, Cyprus

Deadline for manuscript submissions

closed (31 July 2022)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/89753

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

